Jeito Capital
VC Fund
Paris, France
Jeito Capital is a global investment company that invests in companies in the field of medical innovation. It focuses both on financing ground-breaking medical innovation and promoting positive societal impact. It empowers and supports entrepreneurs through its expert, integrated, multi-talented team.The company was founded in 2018 and is basedin Paris with a presence in Europe and the United States.
- Total investments:
- 45
- Last investment:
- Lead investor:
- 67%
- Fund size:
- $1.2B
- Last fund:
Last updated:
For AI agents: llms.txt
Industries Jeito Capital invests in
Stages Jeito Capital invests in
Countries Jeito Capital invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Investment Focus
Industry
- Biotechnology 21 (47%)
- Health Care 9 (20%)
- Therapeutics 9 (20%)
- Medical 6 (13%)
- Pharmaceutical 6 (13%)
Stage
- Series A 12 (27%)
- Series B 9 (20%)
- Series C 4 (9%)
- Series D 3 (7%)
- Seed 1 (2%)
Country
- United States 7 (16%)
- France 5 (11%)
- Switzerland 4 (9%)
- Belgium 2 (4%)
- United Kingdom 2 (4%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Rafaele Tordjman
Founder & CEO
|
Founder & CEO | Total investments: 21 | Find email | |
Julien Elric
Senior Principal
|
Senior Principal | Total investments: 1 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Bionyra Pharma is a clinical-stage biopharmaceutical startup developing next-generation biologics for serious immune-mediated inflammatory diseases. | $165M / Series A / Jun 22, 2026 | ||
| Alveus Therapeutics is a clinical-stage biotech company developing therapies for obesity and metabolic diseases. | $197M / Series A / Jan 08, 2026 | ||
| Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $213M / Series D / Sep 10, 2025 | ||
| ReproNovo is providing patients all over the world with significant improvement by developing cutting-edge therapeutic solutions for uterine disorders including adenomyosis and for male and female infertility. | $65M / Series A / May 21, 2025 | ||
| Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $147.6M / Series B / May 13, 2025 | ||
| Augustine Therapeutics company is a two drug discovery programs to identify novel generations of selective HDAC6 inhibitors for the treatment of axonopathies such as Charcot Marie Tooth disease. These new compounds have the potential to protect from nerve degeneration and promote peripheral myelin and axon repair. | $83.9M / Series A / Mar 24, 2025 | ||
| Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits. | $187M / Series A / Mar 03, 2025 | ||
| XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively. | $67.5M / Series B / Jan 07, 2025 | ||
| Aviceda Therapeutics is a late-stage, pre-clinical biotech company developing drugs for treating glyco-immune diseases. The company focuses on the next generation of immunomodulators by harnessing the power of glycobiology to address the innate immune system and chronic non-resolving inflammation specifically and profoundly. A combination ofcutting-edge technologies and deep biological insights form Aviceda’s engine of transformative product creation.Aviceda uses its cell-based high-throughput screening (HTS) platform to rapidly screen, select, and optimize ligands based on maximum affinity and specificity for each different type of innate immune cell. . The company's products are for eye diseases, fibrosis, neurology, and oncology, for eye diseases like AVD-104, AVD-302, AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma respectively AVD-601, AVD-701 and AVD-801 for oncology, neurology, and fibrosis respectively. | $207.5M / Series C / Jan 07, 2025 | ||
| Noema Pharma is a biotech company developing groundbreaking therapies to address the most disabling symptoms in orphan conditions of the brain and nervous system. Noema’s research and development is focused on understanding and meeting patient needs using our novel therapies. | $147.2M / Series B / Dec 11, 2024 | ||
| See all 45 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Jeito Capital invest in?
Jeito Capital invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 45 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Jeito Capital?
Public channels for Jeito Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Jeito Capital?
The team at Jeito Capital includes Rafaele Tordjman (Founder & CEO) and Julien Elric (Senior Principal). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
